newsfilter
← Latest News
GlobeNewswire·

PMV Pharmaceuticals Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a TP53 Y220C Mutation

Updated PC14586 Phase 1 data presented today as a late-breaking poster at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsConfirmed responses observed in multiple tumor types